UA130613C2 - Заміщене похідне тетрагідроізохіноліну як позитивний алостеричний модулятор d1 - Google Patents

Заміщене похідне тетрагідроізохіноліну як позитивний алостеричний модулятор d1

Info

Publication number
UA130613C2
UA130613C2 UAA202106080A UAA202106080A UA130613C2 UA 130613 C2 UA130613 C2 UA 130613C2 UA A202106080 A UAA202106080 A UA A202106080A UA A202106080 A UAA202106080 A UA A202106080A UA 130613 C2 UA130613 C2 UA 130613C2
Authority
UA
Ukraine
Prior art keywords
disease
formula
compound
pharmaceutically acceptable
parkinson
Prior art date
Application number
UAA202106080A
Other languages
English (en)
Ukrainian (uk)
Inventor
Анне Валаде
Original Assignee
Юсб Біофарма Срл
Юсб Биофарма Срл
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Юсб Біофарма Срл, Юсб Биофарма Срл filed Critical Юсб Біофарма Срл
Publication of UA130613C2 publication Critical patent/UA130613C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
UAA202106080A 2019-07-01 2020-06-29 Заміщене похідне тетрагідроізохіноліну як позитивний алостеричний модулятор d1 UA130613C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19183641 2019-07-01
PCT/EP2020/068181 WO2021001286A1 (en) 2019-07-01 2020-06-29 A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator

Publications (1)

Publication Number Publication Date
UA130613C2 true UA130613C2 (uk) 2026-04-01

Family

ID=67137842

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA202106080A UA130613C2 (uk) 2019-07-01 2020-06-29 Заміщене похідне тетрагідроізохіноліну як позитивний алостеричний модулятор d1

Country Status (28)

Country Link
US (1) US12358890B2 (cg-RX-API-DMAC7.html)
EP (1) EP3993795B1 (cg-RX-API-DMAC7.html)
JP (1) JP7618597B2 (cg-RX-API-DMAC7.html)
KR (1) KR102949226B1 (cg-RX-API-DMAC7.html)
CN (1) CN114008032B (cg-RX-API-DMAC7.html)
AR (1) AR119317A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020299705B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021022379A2 (cg-RX-API-DMAC7.html)
CA (1) CA3139622A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021002949A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021017740A2 (cg-RX-API-DMAC7.html)
EC (1) ECSP22007557A (cg-RX-API-DMAC7.html)
ES (1) ES3069145T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20260599T1 (cg-RX-API-DMAC7.html)
IL (1) IL289317B2 (cg-RX-API-DMAC7.html)
MA (1) MA56445B1 (cg-RX-API-DMAC7.html)
MX (1) MX2021015872A (cg-RX-API-DMAC7.html)
MY (1) MY210362A (cg-RX-API-DMAC7.html)
PE (1) PE20220373A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021552819A1 (cg-RX-API-DMAC7.html)
PL (1) PL3993795T3 (cg-RX-API-DMAC7.html)
RS (1) RS68243B1 (cg-RX-API-DMAC7.html)
SA (1) SA521431274B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202112539XA (cg-RX-API-DMAC7.html)
TW (1) TWI842923B (cg-RX-API-DMAC7.html)
UA (1) UA130613C2 (cg-RX-API-DMAC7.html)
WO (1) WO2021001286A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202109194B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020131671A1 (en) 2018-12-18 2020-06-25 Eli Lilly And Company Dose regimens for use of ly3154207 in the treatment of dopaminergic cns disorders
EP4200280B1 (en) 2020-10-07 2024-02-21 Eli Lilly And Company Phenyl-3,4-dihydroisoquinolin-2(1h)-yl-ethan-1-one derivatives as dopamine d1 receptor positive allosteric modulators
CN117337173A (zh) * 2021-03-09 2024-01-02 伊莱利利公司 美维达林和其他d1正向别构调节剂用于减缓帕金森氏病进展的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010520217A (ja) 2007-03-01 2010-06-10 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒスタミンh3受容体のモジュレーターとしてのテトラヒドロイソキノリン化合物
KR101284796B1 (ko) 2011-10-05 2013-07-10 (주)포인트엔지니어링 캔 패지키 타입의 광 디바이스 제조 방법 및 이에 의해 제조된 광 디바이스
US9278960B2 (en) 2011-11-03 2016-03-08 Merck Sharp & Dohme Corp. Quinoline carboxamide and quinoline carbonitrile derivatives as mGluR2-negative allosteric modulators, compositions, and their use
JO3316B1 (ar) 2013-05-30 2019-03-13 Lilly Co Eli مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل
EA035544B1 (ru) 2014-10-08 2020-07-03 Юсб Байофарма Спрл Производные тетрагидроизохинолина
CN108884050B (zh) * 2016-04-13 2022-07-05 Ucb生物制药私人有限公司 四氢异喹啉衍生物
EP3596060B1 (en) * 2017-03-16 2023-09-20 F. Hoffmann-La Roche AG New bicyclic compounds as atx inhibitors
TWI725408B (zh) 2018-04-20 2021-04-21 美商美國禮來大藥廠 多巴胺d1受體正向異位調節劑

Also Published As

Publication number Publication date
BR112021022379A2 (pt) 2022-03-08
AU2020299705B2 (en) 2026-03-19
US12358890B2 (en) 2025-07-15
CN114008032B (zh) 2023-11-10
AU2020299705A1 (en) 2021-12-09
IL289317B2 (en) 2025-09-01
SA521431274B1 (ar) 2024-01-09
US20220251064A1 (en) 2022-08-11
CO2021017740A2 (es) 2022-01-17
IL289317A (en) 2022-02-01
JP7618597B2 (ja) 2025-01-21
KR20220029687A (ko) 2022-03-08
MX2021015872A (es) 2022-02-03
EP3993795A1 (en) 2022-05-11
TW202115009A (zh) 2021-04-16
SG11202112539XA (en) 2021-12-30
IL289317B1 (en) 2025-05-01
TWI842923B (zh) 2024-05-21
AR119317A1 (es) 2021-12-09
ZA202109194B (en) 2023-11-29
KR102949226B1 (ko) 2026-04-06
CA3139622A1 (en) 2021-01-07
PE20220373A1 (es) 2022-03-16
MA56445B1 (fr) 2026-05-26
ECSP22007557A (es) 2022-02-25
PH12021552819A1 (en) 2022-09-28
CL2021002949A1 (es) 2022-07-15
HRP20260599T1 (hr) 2026-06-05
CN114008032A (zh) 2022-02-01
MA56445A (fr) 2022-05-11
MY210362A (en) 2025-09-13
PL3993795T3 (pl) 2026-07-20
EP3993795C0 (en) 2026-04-22
EP3993795B1 (en) 2026-04-22
WO2021001286A1 (en) 2021-01-07
ES3069145T3 (en) 2026-06-04
RS68243B1 (en) 2026-07-31
JP2022537994A (ja) 2022-08-31

Similar Documents

Publication Publication Date Title
TWI875776B (zh) 作為d1正向異位調節劑之經取代的四氫異喹啉衍生物及其用途
BR112017007123B1 (pt) Composto representado pela fórmula (i-a), ou um seu sal farmaceuticamente aceitável, uso de um composto de fórmula (ia) e composição farmacêutica
US12358890B2 (en) Substituted tetrahydroisoquinoline derivative as a D1 positive allosteric modulator
JP7777589B2 (ja) ジヒドロイソキノリニル誘導体
EP4263517B1 (en) A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator
RU2824527C2 (ru) Замещенное производное тетрагидроизохинолина как позитивный аллостерический модулятор d1
TW202304885A (zh) 新穎的NR2B之環戊烷并[c]吡咯負性異位調節劑
HK40060812B (en) A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator
RU2824581C2 (ru) Замещенное производное тетрагидроизохинолина как позитивный аллостерический модулятор d1
CN110869375B (zh) 2-氧代-1-咪唑烷基咪唑并噻二唑衍生物
HK40060812A (en) A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator
HK40058931B (en) A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator
HK40058931A (en) A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator